How Aripiprazole’s Promise for Treating Autism Fell Short
How Aripiprazole’s Promise for Treating Autism Fell Short
Aripiprazole, marketed as Abilify, is widely thought to be safer than risperidone, the only other drug approved for use in autistic children. A decade’s worth of data suggests that is not true.
How Aripiprazole’s Promise for Treating Autism Fell Short
How Aripiprazole’s Promise for Treating Autism Fell Short

Aripiprazole, marketed as Abilify, is widely thought to be safer than risperidone, the only other drug approved for use in autistic children. A decade’s worth of data suggests that is not true.

Aripiprazole, marketed as Abilify, is widely thought to be safer than risperidone, the only other drug approved for use in autistic children. A decade’s worth of data suggests that is not true.

pharma & biotech
Judge Rules Unreported Clinical Trial Data Must Be Made Public
Judge Rules Unreported Clinical Trial Data Must Be Made Public
Amy Schleunes | Feb 26, 2020
The sponsors of upwards of 1,000 clinical trials may be forced to publish data that have gone unpublished over a 10-year period.
Flu and HIV Drugs Show Efficacy Against Coronavirus
Flu and HIV Drugs Show Efficacy Against Coronavirus
Catherine Offord | Feb 3, 2020
Combining the medications improved conditions in patients with severe 2019-nCoV infections, say doctors in Thailand.
Gene Therapy Finds a Fertile Home in Ohio
Gene Therapy Finds a Fertile Home in Ohio
Shawna Williams | Jan 13, 2020
The midwestern state has quietly laid the groundwork for a biotech hub.
Lottery Underway for Rare Muscle-Wasting Disease Gene Therapy
Lottery Underway for Rare Muscle-Wasting Disease Gene Therapy
Lisa Winter | Jan 7, 2020
The announcement by Novartis, the maker of Zolgensma, has drawn mixed reactions from the spinal muscular atrophy community.
FDA Approves Previously Rejected Muscular Dystrophy Treatment
FDA Approves Previously Rejected Muscular Dystrophy Treatment
Emily Makowski | Dec 13, 2019
The drug Vyondys 53 has met a surrogate endpoint of protein production, but there’s no clear proof it has a clinical benefit.
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Shawna Williams | Dec 6, 2019
The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.
Monthly Contraceptive Pill Shows Promise in Pig Study
Monthly Contraceptive Pill Shows Promise in Pig Study
Catherine Offord | Dec 5, 2019
A device that releases synthetic hormones slowly over time could one day provide a more practical alternative to daily birth control pills, say scientists.
Former FDA Commissioner Frank Young Dies
Former FDA Commissioner Frank Young Dies
Jef Akst | Dec 2, 2019
The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Emily Makowski | Nov 25, 2019
The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.